Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The study aimed at evaluating whether current 24 weeks length of combination treatment is
appropriate or not for patients with HCV genotype 3 infection.